The mysterious lipoprotein(a): moving towards further understanding of its atherogenic role
- PMID: 39418090
- DOI: 10.1093/eurjpc/zwae321
The mysterious lipoprotein(a): moving towards further understanding of its atherogenic role
Conflict of interest statement
Conflict of interest: V.Z.R. reports consultancies and talks sponsored by Abbott, Aché, Amgen, Biolab, Daiichi-Sankyo, GSK, Libbs, Novartis, Novo Nordisk, and Sanofi/Regeneron. R.D.S. reports consultancies and talks sponsored by Aché, Amgen, Amryt, Daiichi-Sankyo, Eli-Lilly, Esperion, Ionis, Kowa, Libbs, Merck, Novartis, Novo Nordisk, PTC Therapeutics, Sanofi/Regeneron, and Torrent. He also reports receiving a scholarship from Conselho Nacional de Pesquisa e Desenvolvimento Tecnológico, Brazil, (CNPq) #303771/2023-2.
Comment on
-
Genetically predicted lipoprotein(a) associates with coronary artery plaque severity independent of low-density lipoprotein cholesterol.Eur J Prev Cardiol. 2025 Jan 27;32(2):116-127. doi: 10.1093/eurjpc/zwae271. Eur J Prev Cardiol. 2025. PMID: 39158116 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
